Evidence map›Paper›PMID 37602759›Full record

ArticleGigaScience2022

KGML-xDTD: a knowledge graph-based machine learning framework for drug treatment prediction and mechanism description.

Chunyu Ma, Zhihan Zhou, Han Liu, David Koslicki

Open access · goldAbstract read
In one paragraph

Article in GigaScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Artemis: Harnessing Knowledge Graphs for Next-Generation Drug Target Prioritization.Computational and structural biotechnology journal · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. MetagenomicKG: a knowledge graph for metagenomic applications.bioRxiv : the preprint server for biology · 2024
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chunyu MaHuck Institutes of Life Sciences, Pennsylvania State University, State College, PA 16801, USA.ORCID 0000-0001-9731-5153
Zhihan ZhouDepartment of Computer Science, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0002-1473-9071
Han LiuDepartment of Computer Science, Northwestern University, Evanston, IL 60208, USA.
David KoslickiHuck Institutes of Life Sciences, Pennsylvania State University, State College, PA 16801, USA.ORCID 0000-0002-0640-954X
Northwestern University · USPennsylvania State University · US

Funding

Biomedical Data Translator Development of Autonomous Relay Agent: ARAXOT2TR003428 · NCATS · OREGON STATE UNIVERSITY · PI DEUTSCH, ERIC, KOSLICKI, DAVID · 2020 to 2024
$5.6M
NCATS NIH HHS OT2 TR003428
6 · The paper itself

Abstract

backgroundComputational drug repurposing is a cost- and time-efficient approach that aims to identify new therapeutic targets or diseases (indications) of existing drugs/compounds. It is especially critical for emerging and/or orphan diseases due to its cheaper investment and shorter research cycle compared with traditional wet-lab drug discovery approaches. However, the underlying mechanisms of action (MOAs) between repurposed drugs and their target diseases remain largely unknown, which is still a main obstacle for computational drug repurposing methods to be widely adopted in clinical settings.

resultsIn this work, we propose KGML-xDTD: a Knowledge Graph-based Machine Learning framework for explainably predicting Drugs Treating Diseases. It is a 2-module framework that not only predicts the treatment probabilities between drugs/compounds and diseases but also biologically explains them via knowledge graph (KG) path-based, testable MOAs. We leverage knowledge-and-publication-based information to extract biologically meaningful "demonstration paths" as the intermediate guidance in the Graph-based Reinforcement Learning (GRL) path-finding process. Comprehensive experiments and case study analyses show that the proposed framework can achieve state-of-the-art performance in both predictions of drug repurposing and recapitulation of human-curated drug MOA paths.

conclusionsKGML-xDTD is the first model framework that can offer KG path explanations for drug repurposing predictions by leveraging the combination of prediction outcomes and existing biological knowledge and publications. We believe it can effectively reduce "black-box" concerns and increase prediction confidence for drug repurposing based on predicted path-based explanations and further accelerate the process of drug discovery for emerging diseases.

Indexed as

Drug DiscoveryPattern Recognition, AutomatedHumansKnowledgeMachine LearningProbabilitybiomedical knowledge graphdrug repurposingreinforcement learning

Identifiers

PMID37602759
PMCPMC10441000
OpenAlexW4386020026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.